top of page

PIPELINE

Creating Transformative Solutions for Patients

Superior Pharmacokinetics Profile

INR301 is a novel, next-generation anti-PD-L1 antibody designed to penetrate the blood-brain barrier with high brain bioavailability without diminishing the systemic exposure.​

Brain PK profiles in AD mice​

Biomarkers in the subiculum of AD mice at 1 month after single IV injection

Plasma PK profiles in AD mice​

Biomarkers in the subiculum of AD mice at 1 month after single IV injection

Brain and plasma PK profiles of control antibody
and INR301 at various time points in AD mice.

Superior Efficacy Profile

Our multimodal approach, targeting the immune checkpoint in the AD brain, significantly reduces GFAP (a marker for reactive astrocytes), amyloid beta plaques, and phosphorylated tau proteins.

Biomarkers in the subiculum of AD mice at 1 month after single IV injection

Biomarkers in the subiculum of AD mice at 1 month after single IV injection

Click for graph

Biomarkers in the subiculum of AD mice at 1 month after single IV injection
Biomarkers in the subiculum of AD mice at 1 month after single IV injection
Biomarkers in the subiculum of AD mice at 1 month after single IV injection
Biomarkers in the subiculum of AD mice at 1 month after single IV injection

Mode of Action

Increasing evidence suggests that immune dysregulation, stemming from chronic and imbalanced inflammatory responses in the brain, underlies the pathophysiology of Alzheimer's disease (AD). Reprogramming the immune crosstalk among astrocytes, microglia, and neurons through the PD-1/PD-L1 immune checkpoint presents a novel therapeutic approach. INR301 is a first-in-class BBB-penetrating anti-PD-L1 antibody, a new treatment paradigm for AD by restoring immune balance in the brain.

INR301 treatment

INR301 treatment

Click for immunostaining

Alzheimer's disease

Alzheimer's disease

Click for immunostaining

INR301 targets PD-L1+ reactive astrocyte in the brain of AD mice​

INR301 targets PD-L1+ reactive astrocyte in the brain of AD mice​

PD-1 and PD-L1 interaction in the brain of AD mice​

PD-1 and PD-L1 interaction in the brain of AD mice​

INR301 treatment

INR301 treatment

Click for immunostaining

Alzheimer's disease

Alzheimer's disease

Click for immunostaining

INR301 targets PD-L1+ reactive astrocyte in the brain of AD mice​

INR301 targets PD-L1+ reactive astrocyte in the brain of AD mice​

PD-1 and PD-L1 interaction in the brain of AD mice​

PD-1 and PD-L1 interaction in the brain of AD mice​

Discovery

Pre-Clinical

Early Clinical

Late Clinical

Candidate

Target

Indication

INR303

Undisclosed

Neurodegeneration

INR302

Undisclosed

Alzheimer's

INR301

PD-L1

Alzheimer's

TRANSMAB® Platform

Candidate
Target
Indication
Discovery
Pre-Clinical
Early Clinical
Late Clinical
INR301
PD-L1
Alzheimer's
INR302
Undisclosed
Alzheimer's
INR303
Undisclosed
Neurodegeneration
bottom of page